Description of investigation

CDC, the Food and Drug Administration (FDA)External Web Site Icon, and the Connecticut Departments of Public Health and Consumer Protection are investigating a fatal case of gastrointestinal (GI) mucormycosis in a premature infant born at 29 weeks’ gestation. The infant received Solgar ABC Dophilus lot 074024-01R1 and subsequently developed signs and symptoms consistent with necrotizing enterocolitis (NEC). Surgical exploration of the infant’s GI tract revealed a necrotic bowel, which was resected; histopathology results from the resected bowel revealed a heavy fungal burden with an organism consistent with a mucormycete. Immunohistochemical staining of the tissue block performed locally and at CDC was positive when tested with a monoclonal antibody known to react with several mucormycete fungal agents. Sequencing of fungal DNA from the tissue identified the mucormycete asRhizopus oryzae.

Solgar ABC Dophilus is a probiotic product intended to contain two bacteria, Bifidobacterium lactis andLactobacillus rhamnosus, and has been used to prevent NEC in premature infants.  This product is available for purchase in retail stores and from online retailers and is used in healthcare settings.

Solgar voluntarily recalledExternal Web Site Icon lots 074024-01R1, 074024-01, and 074024-02 (expiration date 7/31/15) on November 14, 2014. This product was distributed domestically to 29 states and Puerto Rico (see map below) and was distributed internationally to the United Kingdom and Israel.

The investigation into this fatal case of GI mucormycosis and its association with the contaminated Solgar ABC Dophilus is ongoing. CDC currently recommends that Solgar ABC Dophilus should not be used, especially in infants who may be more susceptible to infection, until further information regarding the safety of this product is available.

Domestic distribution of recalled Solgar ABC Dophilus

Solgar, Inc.’s ABC Dophilus Powder Distribution Across the United States (29) and Puerto Rico

Domestic distribution of recalled Solgar ABC Dophilus.  States include: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Indiana, Illinois, Iowa,Kentucky, Nebraska, Nevada, Maine, Massachusetts, Michigan, Missouri, New Jersey, Ohio, Oklahoma, Pennsylvania, New York, North Carolina, Tennessee, Texas, Utah, Vermont,Washington, and Wisconsin.  Puerto Rico is also included.

Top of Page

Laboratory investigation

Local product testing of unopened Solgar ABC Dophilus Powder from lot 074024-01R1 revealed mold growth. Mold from the local product testing was sent to CDC, where it was confirmed to be Rhizopus oryzae, a cause of mucormycosis in humans. CDC laboratory testing of gastrointestinal tissue from the infant also revealed invasive mucormycosis through histopathology and immunochemistry as well as evidence of DNA from Rhizopus oryzae. 

Advice to consumers

  • DO NOT use Solgar ABC Dophilus while this investigation is ongoing.
    • If consumers find that they have used or unused Solgar ABC Dophilus, they should be aware that lots 074024-01R1, 074024-01, and 074024-02 (expiration date 7/31/15) have been voluntarily recalled by the company with instructions for consumers to return their product to the place of purchase for a full refund.
  • Contact your healthcare provider if you are experiencing signs or symptoms consistent with a gastrointestinal mucormycosis infection such as abdominal pain, nausea, or vomiting AND have ingested Solgar ABC Dophilus within the past 30 days.

Advice to healthcare providers

Healthcare facilities and providers should stop using Solgar ABC Dophilus, especially among infants who may be more susceptible to infection with mucormycosis, while this investigation is ongoing. Healthcare providers are asked to report the following to their state or local health departments if they occurred since November 1, 2013:

  • Confirmed or suspected cases of infants with gastrointestinal mucormycosis (diagnosed via culture or histopathology) since November 1, 2013, OR
  • Unexplained infant deaths  within 30 days of receipt of Solgar ABC Dophilus
Microscopic view of Rhizopus oryzaePhotomicrograph ofRhizopus oryzae

Clinical signs and symptoms of mucormycosis

Mucormycosis is a rare infection caused by a group of molds called mucormycetes. These fungi are common in the environment.Rhizopus is one of the most common types of mold that causes mucormycosis.

Mucormycosis can affect a variety of organ systems, with rhinocerebral (sinuses and brain) and pulmonary (lung) infections being the most common forms. In general, the symptoms of mucormycosis depend on the body site where the infection occurs. The clinical hallmark of mucormycosis is the rapid onset of tissue necrosis (tissue death) with or without fever. Necrosis is the result of invasion of blood vessels and subsequent thrombosis (blood clotting).

Gastrointestinal mucormycosis is thought to occur after a person ingests the mold, and it usually affects persons who do not have the normal ability to fight off infection, such as severely malnourished people or transplant recipients. The stomach, colon, and ileum are the most commonly involved sites. The symptoms may be very non-specific and include abdominal pain and swelling, nausea, and vomiting.

ما را در شبکه های اجتماعی دنبال کنید: